NCT00520481View on ClinicalTrials.gov

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

August 31, 2013

Conditions
Adenocarcinoma of the Prostate
Interventions
DRUG

IMC-A12 (Cixutumumab)

10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.

Trial Locations (3)

94115

ImClone Investigational Site, San Francisco

97239

ImClone Investigational Site, Portland

98109

ImClone Investigational Site, Seattle

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00520481 - Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter